In 2005, after several academic papers published by Jonathan Sackner-Bernstein[REF][REF][REF] on the efficacy and side effects of Nesiritide, Johnson & Johnson met with the FDA and altered its stated plans for the drug and agreed to revise its labeling [REF].
Heart doctors at the Cleveland Clinic then voted unanimously not to permit the prescription of the drug to its patients [REF].